|
|
Background: We evaluated the performance of a protein chip assay for the detection of antibodies to hepatitis C virus (HCV) peptides among injection drug abusers (IDAs) by comparing the assay with existing methods, including enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and recombinant immunoblot assay (RIBA).
Methods: Seventy serum samples collected from IDAs were analyzed by protein chip assay. ELISA, RT-PCR, and RIBA assay were used to validate the results.
Results: The protein chips could detect different peptides’ antibodies against HCV-C, HCV-NS3, HCV-NS4, HCV-NS5, and HCV-mix antigen; no cross reactivity between antigens was observed. Results of the protein-chip assay were compared with those of ELISA. Any inconsistency in results was validated by both RT-PCR and RIBA. Concordance between the results of the protein-chip assay and ELISA was 96.3% for positive samples and 100% for negative samples. The protein chip had a higher specificity than ELISA, a higher sensitivity than RTPCR, and similar specificity and sensitivity as compared to RIBA. The limit of detection of HCV antibodies in the protein chip assay was examined and calculated by incubation of model array with different dilutions. The protein chip assay required smaller amounts of both samples and reagents; it detected serum antibody in sample quantity as low as 3 ng/mL and at antibody dilution as low as 1:1000; its cost was low as well. The positive rates in the antiC, anti-NS3, anti-NS4, and anti-NS5 groups were significantly associated with levels of HCV RNA and the viral load. The HCV RNA and protein chip positive rate in the injection equipment-sharing group was higher than that in the non-injection equipment-sharing group.
Conclusions: The protein chip assay is a faster and simpler approach to simultaneously screen for all HCV peptide antibodies accurately and to provide a rapid diagnosis of HCV infection in IDAs. The dominant positive HCV peptide antibodies were significantly associated with HCV RNA load, especially in the injection equipment-sharing group.
DOI: 10.7754/Clin.Lab.2017.171028
|
